Fruquintinib-induced reversible posterior leukoencephalopathy syndrome
10.3760/cma.j.cn114015-20240118-00042
- VernacularTitle:呋喹替尼致可逆性后部白质脑病综合征
- Author:
Fenfen QU
1
;
Xinjing WU
1
;
Yongmei HU
1
Author Information
1. 山西医科大学附属运城市中心医院药学部，运城 044000
- Publication Type:Journal Article
- Keywords:
Posterior leukoencephalopathy syndrome;
Receptors, vascular endothelial growth factor;
Fruquintinib;
Adverse drug reactions
- From:
Adverse Drug Reactions Journal
2024;26(12):756-758
- CountryChina
- Language:Chinese
-
Abstract:
A 53-year-old female patient with stage Ⅳa colon cancer received 7 cycles of standard chemotherapy regimen. Due to the progression of the condition, she was treated with fruquintinib (5 mg once daily orally on day 1-21, 28 days as one cycle). After 20 days of treatments, the patient experienced sudden consciousness disorders, accompanied by limb convulsions. Her blood pressure was 200/150 mmHg, with urinary protein (+++). Enhanced MRI showed multiple cortical and subcortical abnormal signals in the bilateral frontal, temporal, parietal, and occipital lobes. Reversible posterior leukoencephalopathy syndrome caused by fruquintinib was considered. Then the drug was discontinued. After 2 days of symptomatic treatments such as oxygen therapy, blood pressure reduction, sedation, and antiepileptic therapy, the patient′s consciousness was improved, no limb convulsions occurred and her blood pressure was 130/80 mmHg. After 8 days of treatments, the patient′s condition stabilized and fruquintinib was given again after reducing the dosage. At an one month follow-up, MRI enhancement showed no significant abnormalities.
